Prognostic implications of depression and inflammation in patients with metastatic lung cancer

• Type of Material: Article
• Authors: Daniel C McFarland, Memorial Sloan Kettering Cancer Center; Rebecca M Saracino, Memorial Sloan Kettering Cancer Center; Andrew Miller, Emory University; William Breitbare, Memorial Sloan Kettering Cancer Center; Barry Rosenfeld, Fordham University; Christian Nelson, Memorial Sloan Kettering Cancer Center
• Language: English
• Date: 2020-12-11
• Publisher: FUTURE MEDICINE LTD
• Publication Version: Final Published Version
• Copyright Statement: © 2020 Future Medicine Ltd
• Final Published Version (URL): http://dx.doi.org/10.2217/fon-2020-0632
• Title of Journal or Parent Work: FUTURE ONCOLOGY
• Volume: 17
• Issue: 2
• Start Page: 183
• End Page: 196
• Grant/Funding Information: This research was supported by a National Institutes of Health (NIH)/National Cancer Institute Cancer Center support grant (P30 CA008748) and the NIH Loan Repayment Program (L30 CA220778).
• Keywords: immune function; depressive symptoms; SURVIVAL; survival; QUALITY-OF-LIFE; Life Sciences & Biomedicine; C-REACTIVE PROTEIN; lung cancer; ANTIDEPRESSANT; HOSPITAL ANXIETY; Science & Technology; inflammation; ASSOCIATIONS; MAJOR DEPRESSION; SLEEP DISTURBANCE; prognosis; Oncology; DOUBLE-BLIND; depression; COLORECTAL-CANCER; C-reactive protein
• Research Categories: Health Sciences, Mental Health

Abstract

Background: Lung cancer-related inflammation is associated with depression. Both elevated inflammation and depression are associated with worse survival. However, outcomes of patients with concomitant depression and elevated inflammation are not known. Materials & methods: Patients with metastatic lung cancer (n = 123) were evaluated for depression and inflammation. Kaplan-Meier plots and Cox proportional hazard models provided survival estimations. Results: Estimated survival was 515 days for the cohort and 323 days for patients with depression (hazard ratio: 1.12; 95% CI: 1.05-1.179), 356 days for patients with elevated inflammation (hazard ratio: 2.85, 95% CI: 1.856-4.388), and 307 days with both (χ2 = 12.546; p < 0.001]). Conclusion: Depression and inflammation are independently associated with inferior survival. Survival worsened by inflammation is mediated by depression-a treatable risk factor.